Recent changes
Pharmaceutically Acceptable Salt and Crystal Form of Tetrahydronaphthalene Derivative
USPTO published patent application US20260098027A1 for a pharmaceutically acceptable salt and crystal form of a tetrahydronaphthalene derivative, specifically covering (S)-3-(5-(4-((1-(4-((1R,2R)-6-hydroxy-2-isobutyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and its preparation method. Inventors include Lina Jia, Junran Yang, Zhenxing Du, Lin Wang, Qiyun Shao, and Jun Feng.
Bristol-Myers Squibb Hemoglobinopathy Treatment Compounds
USPTO published patent application US20260098028A1 by Bristol-Myers Squibb Company covering compounds for treatment of hemoglobinopathies. The application includes claims for pharmaceutical compositions and methods of preventing or treating these blood disorders. The A1 publication followed a September 2025 filing date with European application number 19328416.
Amgen KIF18A Kinase Inhibitor Patent Application for Cancer Treatment
USPTO published Amgen's patent application US20260098029A1 for KIF18A protein-modulating compounds intended to treat cancer and cancer-related diseases. The application discloses compounds of formula (I) with synthetic intermediates, pharmaceutical compositions, and methods of treatment. The 15 named inventors include researchers from Amgen's medicinal chemistry and oncology teams.
Particulate Active Premix Antiperspirant Aluminum Chloride Apr 09
Particulate Active Premix Antiperspirant Aluminum Chloride Apr 09
Active Premix for Antiperspirant Products Patent Application
The USPTO published patent application US20260096962A1 covering a particulate active premix composition for antiperspirant products. The composition combines basic aluminum chloride of formula Al2(OH)3.778Cl2.222 to Al2(OH)5.048Cl0.952, an amino acid, an alkaline earth metal salt, and greater than 1% of an alkali metal salt and/or magnesium chloride. Inventors: Wade Charles Henke, Shawn David McConaughy, and David Frederick Swain.
L'OREAL UV Absorbing System with Oil for Preventing Material Aggregation
The USPTO published L'OREAL's patent application (US20260096963A1) for a UV absorbing composition combining physical UV-attenuating materials with oils to inhibit particle aggregation. The invention targets improved stability in sunscreen and cosmetic formulations. The application was filed on October 4, 2024, under application number 18906290.
UV-Absorbing Emulsion with Physical UV-Attenuating Material, Surfactant, and Thickener
USPTO published L'OREAL's patent application (US20260096964A1) for UV-absorbing emulsion compositions containing physical UV-attenuating material, surfactant, and thickening agents. The application was filed on October 4, 2024, under Application No. 18906424. Inventors include Anil Shah, David Enoch Gee II, Brian Bodnar, and Margaret Kindschuh. This patent publication affects cosmetics and personal care product manufacturers developing UV-protective formulations. Companies should review the claims to assess potential overlap with their own product development pipelines and IP strategies.
L'OREAL UV Emulsion Patent with Physical UV-Absorbing System
USPTO published L'OREAL's patent application US20260096965A1 for emulsion compositions containing a UV-absorbing system with physical UV-attenuating material and spherical plus amorphous particulate materials. The patent covers methods of making and using such compositions for UV protection. The application was filed October 4, 2024.
L'OREAL UV Absorbing Composition with Physical Filters and Three Emollients
USPTO published L'OREAL's patent application (US20260096966A1) for a UV-absorbing composition combining at least one physical UV-attenuating material with an emollient system containing at least three emollients. The invention includes methods of making and using such compositions for topical applications. The application was filed on October 3, 2025, under Application No. 19349244.
UV Absorbing System With Physical Material Coloring Agent
USPTO published L'OREAL's patent application (US20260096967A1) for UV-absorbing compositions containing physical UV-attenuating materials and coloring agents. The application covers methods of making and using such cosmetic compositions for sun protection. The application was filed October 3, 2025.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
691 changes in last 7 days
Latest high priority updates
140 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.